SEMA4D: A Potential Drug Target and Biomarker (G10507)

Target Name: SEMA4D

NCBI ID: G10507

SEMA4D

SEMA4D: A Potential Drug Target and Biomarker

Semaglutide, a drug used to treat type 2 diabetes, has been shown to have a unique mechanism of action that involves modulating the gut microbiome.1 SEMA4D is a protein that consists of four domains: semaglutide, immunoglobulin domain (Ig), transmembrane domain (TM), and short cytoplasmic domain (semaphorin) 4D.2 SEMA4D has been shown to have various functions in the body, including its role in the regulation of inflammation and autophagy.3

The SEMA4D gene was first identified in 2008 and has since been shown to encode a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract.4 SEMA4D has been shown to have a unique structure that is distinct from other proteins that encode similar domains, such as the semaglutide domain found in semaglutide.5

SEMA4D has been shown to have various functions in the body, including its role in the regulation of inflammation and autophagy.6 SEMA4D has been shown to have a unique structure that is distinct from other proteins that encode similar domains, such as the semaglutide domain found in semaglutide.7

SEMA4D has been shown to have a role in the regulation of inflammation, with studies showing that SEMA4D can inhibit the production of inflammatory cytokines.8 SEMA4D has also been shown to have a role in the regulation of autophagy, with studies showing that SEMA4D can promote the clearance of damaged or dysfunctional cells.9

SEMA4D has been shown to have a role in the regulation of the immune system, with studies showing that SEMA4D can modulate the production of antibodies.10 SEMA4D has also been shown to have a role in the regulation of cell signaling pathways, with studies showing that SEMA4D can interact with various signaling molecules and regulate the production of various signaling proteins.11

SEMA4D has been shown to have a role in the regulation of inflammation and autophagy, and these functions have led to the hypothesis that SEMA4D may be a drug target for various diseases.12 SEMA4D has also been shown to have a unique structure that is distinct from other proteins that encode similar domains, such as the semaglutide domain found in semaglutide.13

In conclusion, SEMA4D is a protein that has been shown to have various functions in the body, including its role in the regulation of inflammation and autophagy.14 SEMA4D has a unique structure that is distinct from other proteins that encode similar domains and has been shown to have a role in the regulation of various physiological processes in the body.15 Further research is needed to fully understand the functions of SEMA4D and its potential as a drug target or biomarker.16

Protein Name: Semaphorin 4D

Functions: Cell surface receptor for PLXNB1 and PLXNB2 that plays an important role in cell-cell signaling (PubMed:20877282). Regulates GABAergic synapse development (By similarity). Promotes the development of inhibitory synapses in a PLXNB1-dependent manner (By similarity). Modulates the complexity and arborization of developing neurites in hippocampal neurons by activating PLXNB1 and interaction with PLXNB1 mediates activation of RHOA (PubMed:19788569). Promotes the migration of cerebellar granule cells (PubMed:16055703). Plays a role in the immune system; induces B-cells to aggregate and improves their viability (in vitro) (PubMed:8876214). Induces endothelial cell migration through the activation of PTK2B/PYK2, SRC, and the phosphatidylinositol 3-kinase-AKT pathway (PubMed:16055703)

The "SEMA4D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA4D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets